IFM Investors’s Zimmer Biomet ZBH Stock Holding History

IFM Investors’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.95M	Buy	45,881 +1,413	+3%	+$124K	0.03%	462
2026 Q1	$4.02M	Buy	44,468 +3,177	+8%	+$292K	0.03%	425
2025 Q4	$3.71M	Buy	41,291 +92	+0.2%	+$8.72K	0.03%	444
2025 Q3	$4.05M	Hold	41,199	–	–	0.04%	404
2025 Q2	$3.76M	Buy	41,199 +3,624	+10%	+$350K	0.04%	410
2025 Q1	$4.25M	Hold	37,575	–	–	0.05%	363
2024 Q4	$3.97M	Sell	37,575 -4,225	-10%	-$453K	0.04%	384
2024 Q3	$4.51M	Sell	41,800 -854	-2%	-$93.2K	0.04%	374
2024 Q2	$4.63M	Buy	42,654 +135	+0.3%	+$15.9K	0.05%	359
2024 Q1	$5.61M	Sell	42,519 -1,126	-3%	-$141K	0.06%	309
2023 Q4	$5.31M	Hold	43,645	–	–	0.06%	293
2023 Q3	$4.9M	Buy	43,645 +2,178	+5%	+$277K	0.06%	295
2023 Q2	$6.04M	Buy	41,467 +933	+2%	+$127K	0.08%	263
2023 Q1	$5.24M	Buy	40,534 +189	+0.5%	+$23.7K	0.08%	269
2022 Q4	$5.14M	Hold	40,345	–	–	0.09%	266
2022 Q3	$4.22M	Buy	40,345 +2,143	+6%	+$235K	0.08%	275
2022 Q2	$4.01M	Buy	38,202 +5,773	+18%	+$685K	0.07%	291
2022 Q1	$4.15M	Buy	32,429 +3,611	+13%	+$435K	0.06%	296
2021 Q4	$3.55M	Buy	28,818 +444	+2%	+$58.1K	0.07%	297
2021 Q3	$4.03M	Buy	28,374 +1,001	+4%	+$147K	0.08%	237
2021 Q2	$4.27M	Buy	27,373 +4,381	+19%	+$710K	0.09%	232
2021 Q1	$3.57M	Buy	22,992 +2,344	+11%	+$363K	0.1%	219
2020 Q4	$3.09M	Buy	20,648 +3,062	+17%	+$432K	0.1%	207
2020 Q3	$2.32M	Buy	17,586 +1,981	+13%	+$259K	0.1%	196
2020 Q2	$1.81M	Sell	15,605 -5,419	-26%	-$624K	0.09%	219
2020 Q1	$2.01M	Sell	21,024 -780	-4%	-$102K	0.09%	226
2019 Q4	$3.17M	Sell	21,804 -935	-4%	-$129K	0.11%	187
2019 Q3	$3.03M	Buy	22,739 +7,908	+53%	+$1.02M	0.11%	194
2019 Q2	$1.7M	Buy	14,831 +1,621	+12%	+$190K	0.1%	223
2019 Q1	$1.64M	Buy	13,210 +1,131	+9%	+$129K	0.11%	196
2018 Q4	$1.22M	Buy	12,079 +1,036	+9%	+$117K	0.1%	212
2018 Q3	$1.41M	Buy	11,043 +1,526	+16%	+$181K	0.11%	200
2018 Q2	$1.03M	Buy	9,517 +3,096	+48%	+$337K	0.1%	222
2018 Q1	$680K	Buy	6,421 +673	+12%	+$78.2K	0.1%	232
2017 Q4	$673K	Sell	5,748 -20	-0.3%	-$2.26K	0.11%	213
2017 Q3	$656K	Buy	5,768 +233	+4%	+$26.9K	0.11%	212
2017 Q2	$690K	Buy	5,535 +1,347	+32%	+$160K	0.12%	193
2017 Q1	$496K	Buy	4,188 +1,573	+60%	+$178K	0.13%	203
2016 Q4	$262K	Buy	+2,615	New	+$280K	0.12%	218

Other funds holding ZBH

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

WAM

Wilsey Asset Management San Diego, California $681M AUM 6.7% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

QAM

QSM Asset Management London, United Kingdom $193M AUM 47.49% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

NCM

Northside Capital Management Hood River, Oregon $1.22B AUM 20.77% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

GHAM

Gilman Hill Asset Management New Canaan, Connecticut $731M AUM 19.41% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

IFM Investors's ZBH Position: Q2 2026 in Review

IFM Investors increased its Zimmer Biomet (ZBH) stake by 3.2% in Q2 2026, buying an estimated $124K and bringing the position to 45,881 shares worth $3.95M. The position accounts for 0.03% of the portfolio, ranked #462.

IFM Investors first reported a position in ZBH in Q4 2016 and has held it in 39 quarters since. The position peaked at $6.04M in Q2 2023. 150 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.

IFM Investors held 45,881 shares of Zimmer Biomet worth $3.95M as of Q2 2026.
IFM Investors bought 1,413 Zimmer Biomet shares in Q2 2026, an estimated $124K.
Zimmer Biomet made up 0.03% of IFM Investors's portfolio in Q2 2026, its #462 holding.
IFM Investors first reported a position in Zimmer Biomet in Q4 2016 and has held it in 39 quarters since.
IFM Investors's Zimmer Biomet position peaked at $6.04M in Q2 2023.
150 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.

Based on IFM Investors's 13F filing for Q2 2026, filed 21 Jul 2026.